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Purpose or Objective: For NSCLC patients treated with SBRT, 
we investigated if dose to the heart and its substructures is 
associated with non-cancer death. 
 
Material and Methods: From 2006-2013 801 patients with 
early stage NSCLC were treated with CBCT guided SBRT 
(median 54 Gy in 3 fractions) in 5 institutes for whom 
treatment plans were available. 565 patients were analyzed 
after exclusion of synchronous or metachronous tumors 
(n=80), follow-up<1y (n=63), or death from cancer (93).An 
average anatomy was constructed based on 109 patients of 
the 5 institutes using deformable image registration. 
Subsequently, all patients were registered to this average 
anatomy and the corresponding dose distribution was 
deformed accordingly [1]. The heart and substructures right 
atrium, left atrium, right ventricle, left ventricle, superior 
vena cava, descending aorta and left pulmonary artery were 
contoured on the average anatomy. For each (sub)structure 
dosimetric parameters DV (V: 0 cc-max), VD (D: 0 Gy-max), 
EUDn (n: 0.1-10) were obtained.Associations of these 
dosimetric parameters with death were evaluated using 
univariate Cox regression. Per (sub)structure the parameter 
with the lowest Akaike information criterion was selected 
and used in subsequent analyses. Correlations between all 
(sub)structures were assessed prior to inclusion in a 
multivariate Cox regression. Finally, the (sub)structure(s) 
that remained significant in the first multivariate analysis 
were included in a second multivariate analysis, also 
including; performance status, age, gender, biological dose, 
distance to bronchus, comorbidity index, lung-function, 
tumor diameter, T-stage, institute and pack years smoking. 
 
Results: With a median follow-up of 28 months, 58% of 
patients were alive. 3% had a central tumor. Univariate 
analysis showed significant associations between the 
(sub)structures and death. The most predictive parameters 
per (sub)structure are shown in table 1. Correlations between 
the heart and it’s substructures was strong (average 0.7). As 
dose to the heart was also represented by dose to the heart 
substructures, heart_D0 was not included in the multivariate 
analysis. Maximum dose to the left atrium and dose to 2 cc of 
the superior vena cava were significant in the multivariate 
analysis (p=0.033, HR=1.012 and p=0.034, HR=1.022 
respectively). Association between survival and these 
parameters is shown in figure 1.In the second multivariate 
analysis these parameters remained significantly associated 
with death, as well as age (p<0.001, HR=1.034), performance 
status(p=0.004, HR=1.138), comorbidity index (p=0.032, 
HR=1.125), lung-function (p<0.001, HR=0.984) and pack years 
smoking (p=0.004, HR=1.011). 
 
 
 
Conclusion: For these NSCLC patients treated with SBRT we 
found significant associations between non-cancer death and 
the maximum dose on the left atrium, and to the D2cc of the 
superior vena cava. Consequently, heart sparing potentially 
improves outcome. 
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Purpose or Objective: Craniospinal irradiation (CSI) plays an 
important role in the treatment of medulloblastoma and 
improvement in treatment during the last decades has 
resulted in good prognosis. CSI is most commonly delivered 
with photons or a combination of photon/electrons. 
However, proton therapy is generally indicated as it lowers 
the dose to normal tissues and potentially reduces the risk of 
late effect. The aim of this study was therefore to compare 
the estimated risk of cardiac toxicity following CSI using 
photons, electrons and protons. 
 
Material and Methods: CSI treatment plans including 
conformal photons, electrons/photons combined, double 
scattering protons (DS) and intensity modulated proton 
therapy (IMPT) were created in the Eclipse treatment 
planning system [Varian Medical Systems, Palo Alto, CA, USA] 
for six pediatric patients. The CTV included the brain and the 
spinal canal, for the protons the CTV was expanded to also 
include the entire vertebral body to prevent asymmetric 
growth of the skeleton. During treatment planning a setup 
uncertainty of 5 mm was taken into account, as well as an 
uncertainty in the proton range of 3.5 %. The prescribed dose 
for all techniques was 23.4 Gy(RBE). Dose-risk models derived 
from two independent pediatric patient cohorts were used to 
estimate the risk of cardiac toxicity. The excess Relative Risk 
(ERR – relative to general population) for cardiac mortality 
was estimated using a linear model [1], while ERR for cardiac 
failure and disorder were estimated using both a linear and a 
linear-quadratic [2] (LQ) model. Input parameters were the 
mean heart dose, and the parameters (with 95 % Confidence 
Interval (CI)) displayed in Table I. The Relative Risk (RR) was 
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defined as the ratio between ERR for photon /electron, 
photon/DS and photon/IMPT. 
 
 
Results: Regardless of dose-risk model applied, the 
conformal photons were ranked with the highest ERR for all 
cardiac toxicities, whereas IMPT was ranked with the lowest 
(Figure 1a). For cardiac mortality the ERR for photon was 8.1 
(95 % CI: 3.4 to 30.5), while ERR for IMPT were 1.3 (95 % CI: 
1.1 to 2.4). For cardiac disorder and cardiac failure the ERR 
for photon was 5.1 (95 % CI: 0.9 to 15.2) and 2.1 (95 % CI: 0.8 
to 4.6), respectively (Linear model). The corresponding 
results for IMPT were 1.2 (95% CI: 1.0 to 1.7) and 1.1 (95 % 
CI: 1.0 to 1.2). Similar trends were found using the LQ model. 
Relative to IMPT, photons lead to a risk of cardiac mortality 
that was a factor of 6.1 higher (range 5.7 to 7.0), cardiac 
disorder a factor of 4.3 higher (range 4.1 to 4.9) and cardiac 
failure a factor of 2.0 higher (range 1.9 to 2.1) (Figure 1b). 
 
 
 
Conclusion: Across different cardiac morbidity endpoints, 
and despite different dose-risk models used, the results of 
our modelling study were consistently in favour of protons. 
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It has long been hypothesized that the propagation of 
circulating tumour cells (CTCs) is a pre-requisite for the 
development of metastases. However, robust technology to 
reliably isolate CTCs and characterise them at the molecular 
level has only become available in recent years. Thus 
repeated blood sampling for CTCs could provide a non-
invasive method of serially reassessing tumour status and 
evolving tumour biology.  
Patients with stage I-III NSCLC are at high risk of developing 
distant metastases after radiotherapy (RT) or chemo-
radiotherapy treatment. With the advent of new technologies 
to enumerate CTCs, the clinical significance of CTCs before, 
during and after RT has become of great interest. In the 
current era of targeted therapy and the development of 
personalised medicine the question still remains as to 
whether CTCs could be used to identify patients most likely 
to benefit from radical RT and prevent the delivery of futile 
cancer treatments and their associated toxicity. Prospective 
clinical trials have shown the prognostic value of CTC 
enumeration in patients with non-small cell lung cancer 
(NSCLC) and small cell lung cancer (SCLC) (1, 2). Although 
CTCs have been used as a surrogate biomarker in hundreds of 
clinical trials, as yet none have been incorporated into 
standard clinical practice. To date there are few published 
studies evaluating CTC’s in patients undergoing radical 
thoracic RT.  
In my talk I will discuss the following:  
•novel platforms available for isolation of CTCs 
•current data on the evaluation of CTCs as a biomarker in 
NSCLC and SCLC patients treated with RT  
•advantages and limitations of CTCs as a biomarker •future 
directions and the prospect of using CTCs to stratify patients 
in clinical trials 
 
References 
ADDIN EN.REFLIST 1. Krebs MG, Sloane R, PriestL, Lancashire 
L, Hou JM, Greystoke A, et al. Evaluation and 
prognosticsignificance of circulating tumor cells in patients 
with non-small-cell lungcancer. Journal of clinical oncology : 
official journal of the American Societyof Clinical Oncology. 
2011 Apr 20;29(12):1556-63. PubMed PMID: 21422424. 
2. HouJ, Krebs M, Lancashire L, Sloane R, Backen A, Swain R, 
et al. ClinicalSignificance and Molecular Characteristics of 
Circulating Tumor Cells andCirculating Tumor Microemboli in 
Patients With Small-Cell Lung Cancer. Journalof Clinical 
Oncology. 2012 FEB 10 2012;30(5):525-32. PubMed 
PMID:WOS:000302622900018. English. 
 
SP-0402  
The fall and raise of predictive radiotherapy biomarkers 
M. Baumann
1OncoRay – National Center for Radiation Research in 
Oncology, Faculty of Medicine and University Hospital Carl 
Gustav Carus- Technische Universität Dresden, Dresden, 
Germany 
1,2,3,4 
2Helmholtz-Zentrum Dresden - Rossendorf, Institute of 
Radiooncology, Dresden, Germany 
3German Cancer Consortium DKTK Dresden, and German 
Cancer Research Center DKFZ, Heidelberg, Germany 
4Department of Radiation Oncology, Institute Faculty of 
Medicine and University Hospital Carl Gustav Carus- 
Technische Universität Dresden, Radiooncology, Dresden, 
Germany 
 
Radiotherapy is a mainstay of cancer treatment. Due to it 
high efficacy to inactivate cancer stem cells in the primary 
tumor and regional metastases as well as its increasing ability 
to spare normal tissues, it has a proven curative potential in 
